Lege Artis Medicinae

[POST-INFARCTION CARDIAC FAILURE]

TOMCSÁNYI János

JULY 14, 2007

Lege Artis Medicinae - 2007;17(06-07)

[Recent advances in the care of acute myocardial infarction have resulted in more patients surviving myocardial infarction than earlier. However, heart failure is a common complication in these patients, which in turn is associated with substantial mortality, primarily due to a remodelling of the left ventricle that already starts in an early stage of the myocardial infarction. The aim of this review article is to present the pathomechanism of this remodelling and to discuss related therapeutic options. Current guidelines recommend the use of an angiotensin- converting enzyme inhibitor combined with or followed by an angiotensin receptor blocker, a beta-blocker, and an aldosterone antagonist in post-infarction patients with concomitant heart failure.]

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[Clinical consensus conference on COPD]

TAMÁSI Lilla

Lege Artis Medicinae

[THE USE OF BETA RECEPTOR BLOCKERS IN CHRONIC HEART FAILURE]

CZURIGA István

[The beneficial effects of treatment with betablockers in patients with chronic heart failure have been demonstrated in several large, prospective, randomised, placebo-controlled clinical trials. In large trials with mortality as the endpoint, the long-term use of bisoprolol, carvedilol, nevibolol and metoprolol succinate have been associated with a reduction in total mortality, cardiovascular mortality, sudden cardiac death and death due to progression of heart failure in patients of functional classes II-IV. These favorable clinical experiences warrant a recommendation that beta-blockers should be used in all haemodynamically stable heart failure patients with reduced left ventricular systolic function who are on standard treatment, unless contraindicated. In this review, the most important data of clinical trials and practical considerations of therapy with beta-blockers in heart failure are summarized.]

Lege Artis Medicinae

[THE USE OF DIRECT VASODILATORS AND DIGITALIS IN CHRONIC HEART FAILURE]

DÉKÁNY Miklós

[For the optimal treatment of heart failure patients with systolic dysfunction, supplementation of the standard diuretics plus neurohormonal antagonists treatment with the direct vasodilator combination dihydralazine+nitrate, as well as with digitalis may be necessary. Addition of hydralazine/dihydralazine+nitrate to the treatment of chronic heart failure is recommended if ACE-inhibitors or angiotensin-receptor blockers cannot be administered. Beta blockers should also be used in these cases. If symptoms persist or worsen, addition of this combination to the standard therapy is reasonable. Supplementation with digitalis, mostly digoxin should be considered in similar conditions. It can be especially beneficial for patients with high-ventricular-rate atrial fibrillation. To achieve maximal survival benefit, the dose of digoxin must not exceed 0.125 mg/day. Low body weight or muscle mass, significantly reduced renal function may make further dose reduction necessary. If renal function is severely limited, digitoxin instead of digoxin may be used.]

Lege Artis Medicinae

[Addictions in the focus - Readers’ questions answered by dr. János Szemelyácz]

SZEMELYÁCZ János

Lege Artis Medicinae

[RECOGNITION AND MANAGEMENT OF ACUTE HEART FAILURE]

KARLÓCAI Kristóf

[Acute heart failure may develop in previously healthy hearts. Nevertheless, structural abnormalities can facilitate its development and also, chronic heart failure can progress into acute stage. Considering the total cost of care in the patient's life, this is the most expensive heart disease. The clinical signs and physical abnormalities are usually of diagnostic power, however, instrumental investigations are necessary to recognize complications and to guide therapy. Patients should be monitored in well equipped coronary care units. Therapy consists of medications, coronary revascularization and use of mechanical assist devices.]

All articles in the issue

Related contents

Hypertension and nephrology

[Extrapulmonary multiple organ damage and dysfunction in Covid-19]

KÉKES Ede, NAGY Judit

[SARS-CoV-2 virus attacks nőt only the lungs bút alsó many other or- gans (heart, kidney, liver, pancreas, gastrointestinal tract, brain, hematopoiesis) and regulatory system (RAAS, immuné system) to different degrees and with dif- ferent pathomechanisms. Accordingly, cell death, tissue damage and dysfunction or failure of somé organs has been developed. Our paper provides a detailed analysis of the incidence of extrapulmonary lesions, clinical manifestations, and the underlying pathomechanisms. This multi-organ damages was detected dom- inantly in severe Covid cases, bút may occur in moderate or mild cases. It should alsó be taken intő account that the consequences may occur after the acute phase, in a seronegative State - months after the onset of infection. In particu- lar, the heart (myocarditis, coronary insufficiency, arrhythmia), the kidney (acute renal failure and then permanent GFR decrease), glucose metabolism disorder (diabetes worsening, ketoacidosis, new diabetes) are the biggest therapeutic challenge. Multi-organ damage is due to direct virus-induced cell death, endo- thelial cell damage in the vascular system, and thrombo-inflammation with the formation of microthrombi, imbalance in the RAAS regulatory system, and early and delayed abnormal immuné response (cytokine storm).]

Lege Artis Medicinae

[Paradigm shift in the drug therapy of HFrEF]

HEPP Tamás, VARJAS Norbert, BENCZÚR Béla

[The incidence and prevalence of heart failure (HF) is constantly increasing, its mor­bidity and mortality are still high, thus the disease burden is huge and its proper treatment is of paramount importance. Subs­tantial evidence on improving its prognosis remains available only by the treatment of chronic heart failure with reduced left ventricular function (HFrEF). There have been published a number of “milestone” studies in the last decades, the results of which fundamentally determined the HF therapy until recently. Baseline therapy for HFrEF has been placed on three pillars for a long time: angiotensin-converting-en­zyme inhibitors (ACEI), beta-blocker (BB), and mi­ne­ralocorticoid receptor antagonist (MRA) are included in different heart failure guide­lines with I/A level recommendation. The ground-breaking highly important PARADIGM-HF study was published in 2014, and examined an entirely new class of drugs, the sacubitril/valsartan, which belongs to the group of angiotensin receptor blocking/neprilysin inhibitors (ARNI) in HFrEF patients. Results of this study showed that sacubitril/valsartan significantly reduced the primary composite endpoint of CV mortality and HF hospitalization by 20% and reduced overall mortality by 16% compared to an active comparator enalapril, which has the broadest evidence in HFrEF therapy. The 2016 European Society of Cardiology (ESC) HF guidelines recommended the use of sacubitril/valsartan with an I/B evidence level as a replacement for an ACEI to further reducing the risk of HF hospitalization and death of out-patients with HFrEF who remained symptomatic despite optimal treatment with an ACEI, a BB and an MRA. Later, several smaller studies concerned sacubitril/valsartan with slightly different indications and in other patient groups. The PIONEER-HF study demonstrated that early initiation of sacubitril/valsartan therapy after the stabiliza­tion of acute HF is safe and effective in HFrEF patients, reduces more rapidly the NT-proBNP levels - which correlates with HF prognosis -, than the enalapril. The TRANSITION and TITRATION studies provided useful information on the initiation of sacubitril/valsartan therapy and the strategy of dose titration. The appearance of sacubitril/valsartan opened a new era in HFrEF therapy a few years ago, an era we are actually experiencing in Hungary. Thanks to SGLT-2 inhibitors, it is also possible that we are at the door of an even newer therapeutic era. This question is expected to be answered in the new ESC HF-guidelines to be published soon this year. ]

Hypertension and nephrology

[Lupus nephritis, 2022]

CZIROK Szabina, DOLGOS Szilveszter

[The lupus nephritis (LN) is one of the most frequent manifestation of SLE which causes higher morbiditiy and mortalitiy of the patients if it appears. Although the use of glucocorticoides, cyclophosphamide and mycofenolat mofetil and the protection of the kidney with conservative therapy has significantly improved the outcome of the disease, but the long-term renal outcome and risk of death from LN have not changes over the last 20 years. Furthermore, the side effect of our medications used as part of the standard immunomodulatory therapy are not negligible. The better understanding of the pathomechanism of different medical conditions (hypertension, diabetes mellitus etc.) has helped to combine medications with different therapeutic targets which result more effective and favorable side-effect profile therapy. Therefore, it is not suprising that, in parallel with improvement of the immunology, with better knowlege about the patomechanism of SLE can lead to the new combined, targeted treatments which have broadened the therapeutic options. In addition to the immunmodulatory therapy, a drug with new mechanism of action has become available to slow the progression of chronic kidney diseases. The purpose of this summary is to briefly summarize the current knowledge available and assist clinicians in the daily practice of patients with LN to give suggestion for more effective and personalized therapeutic options.]

Hypertension and nephrology

[Echocardiographic judgment of the left ventricular remodelling and heart failure’s types]

HATI Krisztina

[The heart responds to the damage to the heart muscle with various changes that are regulated by complex processes. If the harm is irreversible, changes that begin as an adaptation can become chronic and permanently worsen heart function. The author details below the pathological remodelling of the left ventricle that can lead to heart failure. It covers the types of heart failure based on the latest recommendations and presents the echocardiographic examination methods that can be used to assess the diastolic, systolic and right ventricular function of the heart.]

Hypertension and nephrology

[Diuretikumok hypertoniában - 2010]

BARNA István

[Diuretics (especially thiazide derivatives and indapamide that also has vasodilator efficacy) are considered as first line treatment in hypertension. They are particularly favourable in the treatment of overweight, elderly, isolated systolic hypertensive patients suffering from type 2 diabetes and metabolic syndrome or in mild renal and cardiac insufficiency. They can be ideally combined with other antihypertensive agents (primarily with angiotensin-converting enzyme inhibitors, angiotensin receptor blocking agents és béta-blockers). If hypertension is associated with left ventricular hypertrophy or stroke indapamide is the appropriate choice. In case of left ventricular dysfunction and heart failure thiazide and/or furosemide is the adequate option. Low dose diuretics have no clinically relevant side effects and reduce cardiac mortality to the same extent as other pharmaceutical interventions.]